We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lentigen and the University of Pennsylvania Enter License Agreement for Lentiviral Vector Technology
News

Lentigen and the University of Pennsylvania Enter License Agreement for Lentiviral Vector Technology

Lentigen and the University of Pennsylvania Enter License Agreement for Lentiviral Vector Technology
News

Lentigen and the University of Pennsylvania Enter License Agreement for Lentiviral Vector Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lentigen and the University of Pennsylvania Enter License Agreement for Lentiviral Vector Technology "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lentigen Corporation has announced an exclusive, worldwide licensing agreement with the University of Pennsylvania relating to lentiviral vector technology.

The intellectual property, which was developed at Penn's School of Medicine, has been granted to Lentigen to develop and commercialize products for both research reagents for laboratory research purposes and potentially, therapeutic purposes.    

Dr. Boro Dropulic, Founder and CEO of Lentigen, commented, "Lentigen's license agreement with the University of Pennsylvania is part of our goal to continue licensing lentiviral technology from both academic research institutions and the private sector, which we will then work to commercialize."

Advertisement